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The host defence peptide cathelicidin (LL-37 in humans, mCRAMP in mice) is released from 21 
neutrophils by de-granulation, NETosis and necrotic death; it has potent anti-pathogen activity 22 
as well as being a broad immunomodulator. Here we report that cathelicidin is a powerful Th17 23 
potentiator which enhances aryl hydrocarbon receptor (AHR) and RORγt expression, in a TGF-24 
β1-dependent manner. In the presence of TGF-β1, cathelicidin enhanced SMAD2/3 and STAT3 25 
phosphorylation, and profoundly suppressed IL-2 and T-bet, directing T cells away from Th1 26 
and into a Th17 phenotype. Strikingly, Th17 but not Th1 cells were protected from apoptosis by 27 
cathelicidin. We show that cathelicidin is released by neutrophils in mouse lymph nodes and 28 
that cathelicidin-deficient mice display suppressed Th17 responses during inflammation, but not 29 
at steady state. We propose that the neutrophil cathelicidin is required for maximal Th17 30 
differentiation, and that this is one method by which early neutrophilia directs subsequent 31 
adaptive immune responses. 32 
 33 
INTRODUCTION 34 
The last 20 years have seen a fundamental shift in our understanding of the roles and 35 
capabilities of neutrophils. We are now aware that they can live for much longer than previously 36 
thought (up to 5 or 6 days in vivo [1]); that they move into lymphatics, both during inflammation 37 
and as part of regular homeostatic control [2-8]; that they can have reparative as well as pro-38 
inflammatory roles [9-14]; and that they influence outcomes in chronic inflammatory and 39 
autoimmune diseases, as well as infections [15-17]. As a result, we now recognise neutrophils 40 
as able to influence and shape adaptive immunity in tissues and in lymph nodes, in both 41 
suppressive and activatory manners (reviewed in [18, 19]). For example, neutrophils restrain 42 
Th2 inflammation during asthma [20], suppress dendritic cell (DC) migration to lymph nodes 43 
[21], suppress T cell proliferation in sepsis via Mac-1 [22], and limit humoral responses in lymph 44 
nodes [23]. In contrast, they can also directly present antigen to T cells via MHC class II [24], 45 
cross-present to CD8+ T cells [25], directly stimulate T cell proliferation in response to 46 
superantigen [26], promote type 2 responses in the lung [27], increase DC maturation and co-47 
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stimulatory molecule expression [16, 28-30] and promote T cell function during influenza 48 
infection [31, 32]. 49 
A particular relationship between neutrophils and the IL-17-producing Th17 subset of CD4+ T 50 
cells is now evident. The two cells chemoattract each other to the site of inflammation through 51 
production of CCL20/22, IL-17 and IL-8 [33], and the production of IL-17A and IL-17F by Th17 52 
cells increases epithelial cell release of G-CSF and CXCL8, increasing neutrophil migration and 53 
activation [34]. Following release of extracellular traps, the surviving neutrophil cytoplast 54 
structures can indirectly induce Th17 differentiation in the lung during severe asthma [35]. 55 
Neutrophils also produce the Th17 differentiation cytokine IL-23 [36], their elastase release 56 
processes DC-derived CXCL8 into a Th17-promoting form [37], and in vitro they can induce 57 
Th17 differentiation directly [38]. However, the mechanisms through which this occurs largely 58 
remain unknown.  59 
A major component of neutrophil secondary granules [39, 40] and extracellular traps [41] is the 60 
short helical antimicrobial host defence peptide (HDP) cathelicidin (human hCAP-18/LL-37, 61 
mouse mCRAMP). It can also be produced in to a lesser extent by macrophages, mucosal 62 
epithelium, eosinophils, adipocytes [42] and mast cells. Release of HDP, such as cathelicidin, is 63 
a critical part of the first line innate immune response to infection [43, 44] and it is antibacterial, 64 
antiviral, antifungal and immunomodulatory [45-47], with potent ability to modulate the local 65 
innate and adaptive immune response. Amongst other effects, it can act as a chemoattractant 66 
for immune cells [48, 49], promote protective inflammatory responses and modulate cell death 67 
[50, 51], induce wound healing, re-epithelialization and re-endothelialization [52, 53], allow the 68 
take-up of self-RNA and production of type one interferons by plasmacytoid DC [54, 55] and 69 
inhibit class switching in B cells [56]. 70 
We and others have previously shown cathelicidin to directly and indirectly affect T cell function; 71 
it induces DC to prime increased proliferation and pro-inflammatory cytokine production by 72 
4 
 
CD8+ T cells [57], is a chemoattractant for T cells [48], and, in psoriasis, it is recognised directly 73 
as an autoantigen by CD4+ T cells [58].  74 
The outcome of neutrophil cathelicidin-CD4+ T cell interaction is largely uncharacterised. In this 75 
project we set out to investigate how cathelicidin affected T cell differentiation. We report that 76 
cathelicidin is a potent T cell differentiation factor, which induces Th17 and suppresses Th1 77 
differentiation during inflammation, as well as selectively suppressing death of IL-17 producing 78 
cells. We show that this is partially dependent on both the aryl hydrocarbon receptor and the 79 
presence of TGF-β1 and propose this as a major mechanism by which neutrophils can direct T 80 
cell behaviour during inflammatory disease. 81 
RESULTS  82 
The host defence peptide cathelicidin induces IL-17A production by CD4+ T cells 83 
Following on from reports that neutrophils can induce IL-17A production, we hypothesised that 84 
cathelicidin specifically affects differentiation of Th17 cells. To examine this we exposed splenic 85 
single cell suspensions from C57BL/6J mice to Th17-driving conditions. Some wells were 86 
exposed to the murine cathelicidin mCRAMP at 2.5 µM, which is a physiologically relevant 87 
concentration (with cathelicidin in airway secretions from healthy newborns averaging 2 µM and 88 
from those with pulmonary infections up to 6.5 µM [59]). Analysis was performed using the flow 89 
cytometry gating strategy in Supplementary figure 1. 90 
We noted a consistent increase in the frequency of IL-17A producing CD4+ T cells in culture 91 
following cathelicidin exposure under Th17-driving conditions (Fig1A, B). The total count of 92 
CD4+ cells in culture did not change significantly, from a mean of 33.5 +/- 4.8 x 103 CD4+ T cells 93 
in control samples to 38.1 +/- 5.9 x 103 cells in cathelicidin-exposed samples. Further, we noted 94 
that under non-polarising T cell activation conditions (αCD3/αCD28 stimulation), cathelicidin 95 
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induced no increase in IL-17A production (Fig.1C), indicating this peptide is unable to act alone, 96 
instead boosting pathways which have already been triggered. 97 
Further investigation with whole splenic cultures revealed that this increase was dependent on 98 
both the concentration of cathelicidin present (Fig.1D) and the time in culture (Fig. 1E); 99 
cathelicidin exposure led to a 2.5 fold increase in IL-17A production by day 2 of culture, with 100 
further increases seen on day 3. Not only the frequency of IL-17A+ cells but also the intensity of 101 
IL-17A expression (Fig. 1F) was increased following cathelicidin exposure, with consequent 102 
increased detection of IL-17A by ELISA in cell culture supernatant on day 2 (Fig. 1G).  103 
Th17 cells are characterised by expression of the transcription factor RORγt [60, 61]. In keeping 104 
with this, cathelicidin also induced strong expression of RORγt in CD4+ T cells following 24 105 
hours in culture (Fig.1H,I). To confirm that our cathelicidin-induced cells are indeed Th17 cells, 106 
we co-stained for RORγt and IL-17 and demonstrated that all the IL-17-producing cells induced 107 
by cathelicidin were RORγt+ (Fig1J).  108 
We confirmed that cathelicidin was enhancing differentiation of these cells directly by isolating 109 
splenic CD4+ T cells and exposing them to cathelicidin under Th17-driving conditions (Fig.1K). 110 
IL-17A production by these sorted cells was significantly increased by cathelicidin, with an 111 
average 6.2-fold increase in frequency of RORγt+ IL-17A+ cells after 48 hours’ culture and 4-112 
fold increase after 72 hours’ culture (Fig.1K). 113 
In addition, we assessed phosphorylation of STAT3. STAT3 signalling is required for Th17 but 114 
not Th1 differentiation [62]. In isolated CD4+ T cells exposed to cathelicidin for 24 hours under 115 
Th17 driving conditions, STAT3 phosphorylation was significantly enhanced (Fig1L-N).  116 
Cathelicidin’s induction of IL-17 is dependent on TGF-β1 signalling 117 
Our Th17-driving conditions include αCD3 and αCD28 antibodies, and recombinant IL-6, TGF-118 
β1 and IL-23. To examine whether cathelicidin enhances the signalling of any of these 119 
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mediators specifically, we assessed its impact on RORγt expression in the presence of each 120 
mediator individually. Cathelicidin induced increases in RORγt expression only in the presence 121 
of TGF-β1 (Fig. 2A), with no increases seen in cells treated with IL-6 alone, IL-23 alone or IL-6 122 
and IL-23 in combination. Cathelicidin enhanced RORγt in the presence of TGF-β1 alone, but 123 
peak expression following cathelicidin exposure occurred in the presence of IL-6 as well as 124 
TGF-β1.  125 
We therefore hypothesised that cathelicidin was enhancing TGF-β1 signalling. It was also 126 
possible that the peptide enhanced expression of the TGF-β receptor. Analysis of CD4+ T cells 127 
exposed to cathelicidin in Th17-driving conditions revealed that this receptor – and IL-6R and IL-128 
23R – were unaltered (Fig.2B,C). However, phosphorylation of the Smad2/3 signalling proteins 129 
was significantly increased by cathelicidin exposure (Fig.2D,E). Smad2 and 3 are 130 
phosphorylated following TGF-β1 signalling [63] and so this indicated that cathelicidin was 131 
indeed enhancing this process. 132 
IL-1β has also been shown to induce Th17 differentiation [64, 65]. Cathelicidin induced Th17 133 
differentiation when IL-1β was included in our cultures, but only when TGF-β1 was present, and 134 
this was not enhanced over our normal culture conditions of IL-23, IL-6 and TGF-β1 (Fig2F). 135 
Cathelicidin has been shown to use multiple receptors, including P2X7R, CXCR2, GAPDH and 136 
FPR2 [48, 66-70]. It can also enter cells - including plasmacytoid DC, fibroblasts, CHO epithelial 137 
cells and bladder carcinoma cells - without a receptor, via lipid-raft dependent endocytosis [55, 138 
71]. To determine whether cathelicidin’s increase in IL-17A was dependent on a specific 139 
receptor, we also used the human cathelicidin LL-37 and the matched D-enantiomer LL-37. LL-140 
37 induced the same increase in IL-17A in mouse cells as the murine cathelicidin mCRAMP did; 141 
in addition, the D-form peptide D-LL-37 induced a strong increase in IL-17 (UT cells 9.45 +/- 142 
0.47 %, D-LL-37 16.2 +/- 1.01%) (Fig.2G). These results suggest that cathelicidin is functioning 143 
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to modify CD4+ T cell phenotype in a manner independent of the peptide binding to a receptor 144 
directly. 145 
To examine this further, we performed our Th17 generation assay in the presence of WRW4, an 146 
inhibitor of FPR2, and oxidised ATP (oATP), an inhibitor of P2X7 signalling. Including WRW4 in 147 
our cultures had no impact on total IL-17 production (Fig.2H). However, we noted a 148 
concentration-dependent suppression of cathelicidin’s potentiation of Th17 in the presence of 149 
oATP, with 50nM preventing cathelicidin from enhancing IL-17 production (Fig.2I). This was not 150 
statistically significant owing to an increase in baseline IL-17A production in cells exposed to 151 
oATP. 152 
Together, these results reveal that the antimicrobial peptide cathelicidin significantly promotes 153 
Th17 differentiation and IL-17A production in a TGF- β1 dependent fashion.  154 
Cathelicidin induces IL-17F-producing but not IL-22-producing cells 155 
Th17 cells produce a number of pro-inflammatory cytokines including IL-17A, IL-17F and IL-22 156 
[72-74]. We wondered whether cathelicidin would increase expression of these other cytokines 157 
in addition to IL-17A. Analysis of cathelicidin-exposed CD4+ T cells showed, surprisingly, that 158 
cathelicidin did not boost IL-17A single positive (SP) cells (Fig.3A, B). Instead, IL-17F single 159 
positive and A+F+ double positive cells were significantly increased by treatment (Fig.3 C, D). 160 
Consequently production of IL-17F in the supernatant, as measured by ELISA, was also 161 
increased consistently in every sample, although variability between samples meant this was 162 
not statistically significant (Fig.3E). Interestingly, production of IL-22 was not altered significantly 163 
by cathelicidin (Fig.3F). 164 
 165 
Cathelicidin-mediated enhancement of IL-17A production, but not IL-17F, occurs via the 166 
aryl hydrocarbon receptor 167 
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Next, to understand more about the induction of Th17 cells by cathelicidin, we performed gene 168 
expression analysis on sorted CD4+ T cells exposed to Th17-driving conditions in the presence 169 
or absence of 2.5 µM cathelicidin for 24 hours, using a Nanostring mouse immunology chip. 170 
Following cathelicidin exposure, we noted a consistent, significant decrease in the expression of 171 
a number of genes which suppress the induction or conversion of cells into the Th17 subset  172 
[75-78] including Socs3, Stat1, Irf8, Bcl3 and Ikzf4  (Fig. 4A, B).  173 
In keeping with our initial observations, cathelicidin exposure increased expression of the genes 174 
coding for IL-17A and the Th17 cytokine IL-21 (Fig.3A, C). Intriguingly, cathelicidin also led to a 175 
large increase in expression of the aryl hydrocarbon receptor (AHR) gene Ahr (Fig.4A, C). Flow 176 
cytometric analyses subsequently confirmed an increase in AHR protein following cathelicidin 177 
exposure under Th17-driving conditions (Fig.4D, E), which occurred with increasing time of 178 
exposure to cathelicidin and increasing concentration of the peptide present (Fig.4E, F). The 179 
increase in AHR expression by cathelicidin was significant after one day in culture (Fig.4E), 180 
which is earlier than the IL-17 increase was noted.  181 
AHR is a known Th17 differentiation factor [73, 75, 79] and so we hypothesised that the 182 
cathelicidin-mediated increase in IL-17 was a result of its enhanced expression. To test this, we 183 
used the specific AHR antagonist CH223191 [80]. Use of CH223191 abolished the increase in 184 
IL-17A+F+ double-producing cells induced by cathelicidin, indicating that cathelicidin’s induction 185 
of these Th17 cells is dependent on AHR (Fig.4G). Interestingly, single IL-17F-producing cells 186 
were increased by cathelicidin, as previously shown (Fig.3C), but this increase was not 187 
significantly altered by AHR antagonism (Fig.4H). These results indicate that there are both 188 
AHR-dependent and –independent mechanisms through which cathelicidin promotes Th17 189 
differentiation, with AHR being critical for the enhanced generation of IL-17A producing cells, 190 
but not the increase in cells producing only IL-17F.  191 
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Finally, we questioned whether cathelicidin-mediated enhancement of AHR was the key factor 192 
in Th17 potentiation or whether it also increased the production of AHR ligands. To answer this, 193 
we repeated our Th17 differentiation cultures in IMDM as well as in RPMI. It is known that IMDM 194 
contains more natural AHR ligands which induce Th17 differentiation [81]. Cathelicidin 195 
enhanced Th17 differentiation equally in RPMI and IMDM (Fig.4I), indicating that this 196 
potentiation occurs even when AHR ligands are in excess. This lends support to our hypothesis 197 
that the expression of AHR itself is the key factor in cathelicidin’s enhancement of Th17, 198 
meaning that cathelicidin can potentiate AHR signalling and Th17 differentiation at both high 199 
and lower ligand levels. 200 
Cathelicidin suppresses Th1 differentiation in the presence of TGF-β1 201 
Gene expression analysis also revealed a consistent decrease in Th1-associated genes, 202 
including Il2, Irf8, Stat1, and Xcl1 (Fig.4A) following 24 hours of cathelicidin exposure in cells 203 
differentiating under Th-17 driving conditions. Expression of IL-2 protein was confirmed to be 204 
reduced following cathelicidin exposure on day 2 of culture (Fig.5A), with a striking suppression 205 
of IL-2 production by CD4+ T cells, as measured by ELISA.  Expression of the Th1-associated 206 
transcription factor Tbet (Fig.5B) and production of the key Th1 cytokine IFN-γ (Fig.5C, D) were 207 
also both strongly suppressed by cathelicidin.  208 
It was very interesting that Tbet was suppressed when RORγt was up-regulated, and we 209 
wondered if any double positive (RORγt+ Tbet+ cells) were present in our culture, and whether 210 
they expressed IL-17. We found that under Th17-driving conditions almost all the Tbet+ cells 211 
also expressed RORγt (Fig5E). Tbet single-positive cells were almost abolished in cathelicidin-212 
exposed cultures, and the Tbet+ RORγt+ double positive population was also significantly 213 
suppressed. Instead, cathelicidin polarised the cells to RORγt single expressors (Fig.5E). 214 
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Next, we examined the cytokine production by each of these populations, gating on transcription 215 
factor expression. We noted that cathelicidin strongly suppressed the tiny populations of Th1 216 
cells (RoRγt- Tbet+ IFNγ+), to confirm our previous findings that cathelicidin suppresses Th1 217 
cell differentiation (Fig.5F). We also found that cathelicidin enhanced IL-17 production (total 218 
IL17A+ and IL17F+) by both single expressing RORγt+ and double expressing Tbet+ RORγt+ 219 
cells, although the increase in the latter population was much lower (Fig.5G, H). 220 
It is well known that Th17-driving conditions do suppress IL-2 production and Th1 commitment 221 
[82, 83] and we proposed that cathelicidin boosts this suppression further through enhancing 222 
TGF-β1 signalling. In keeping with this, we determined that cathelicidin had no impact on Tbet 223 
expression in activating non-lineage driving conditions (αCD3, αCD28) but only when TGF-β1 224 
was present (Fig.5I) – and the presence of TGF-β1 alone was sufficient for cathelicidin to induce 225 
this suppression. To confirm this, we analysed production of IFN-γ under Th1-driving and Th2-226 
driving conditions, neither of which include TGF-β1. Cathelicidin did not suppress IFN-γ in these 227 
conditions (Fig.5J). This demonstrates a further enhancement of TGF- β1’s action by 228 
cathelicidin. 229 
Cathelicidin promotes survival of Th17 cells but not Th1 cells 230 
We have shown that cathelicidin promotes increased differentiation of Th17 cells with 231 
suppression of Th1 cells in the presence of TGF- β1. We next investigated whether, in addition 232 
to modulated differentiation of CD4+ T cells, cathelicidin also led to differential survival or 233 
proliferation of particular cell subsets. Cathelicidin has been previously shown to induce death of 234 
certain T cell subsets, including T regulatory cells and CD8+ T cells, although CD4+ T effector 235 
cells were not affected [84, 85]. Our Nanostring gene expression analysis revealed a significant 236 
down-regulation of Fasl and consistent but not significant down-regulation of Fas in sorted CD4+ 237 
T cells 24 hours following cathelicidin exposure (Fig.6A). Subsequently, to determine whether 238 
this led to altered rates of death of CD4+ T cells, we measured annexin V staining and uptake of 239 
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propidium iodide, which together distinguish between live, apoptotic and necrotic cells. Using 240 
this method, we noted that cathelicidin significantly suppressed death of CD4+ T cells, with 241 
effects seen by the first day of culture (Fig.6 B,C). 242 
To investigate suppression of death by cytokine producing cells in particular, uptake of fixable 243 
live dead dyes was assessed (Fig.6D). Interestingly, cathelicidin exposure suppressed death of 244 
IL-17A-producing CD4+ T cells (Fig.6D, E) but not IFN-γ-producing cells (Fig.6F), in the same 245 
samples, under Th17-driving conditions. To our knowledge, this is the first demonstration of a 246 
neutrophil-released peptide, or of any antimicrobial peptide, increasing survival of T cells. These 247 
data raise the possibility that neutrophils may have sophisticated impacts on developing and 248 
skewing T cell immunity during inflammatory disease. It was possible that the increased survival 249 
of T cells exposed to cathelicidin was related to the altered IL-2 concentrations noted earlier. To 250 
test this, we spiked our Th17 cultures with increasing concentrations of recombinant IL-2 and 251 
found no alteration in cathelicidin’s enhancement of survival (Fig.6G).  252 
Another possibility was that cathelicidin induces increased proliferation of Th17 cells but not Th1 253 
cells, and that this contributes to their increased frequency in culture. CD4+ T cells labelled with 254 
CFSE were observed following exposure to cathelicidin. We noted that there was no difference 255 
in the proliferation of RORγt+ Th17 cells at 24 or 48 hours in culture, but at 72 hours differences 256 
were noted (Fig.6H). Surprisingly, cathelicidin induced a suppression in proliferation of RORγt+ 257 
cells at this time point, and this was not rescued by addition of recombinant IL-2. The 258 
proliferation of Tbet+ cells, interestingly, was not suppressed by cathelicidin (Fig.6I,J).  Mice 259 
lacking cathelicidin cannot increase IL-17 production in response to inflammation 260 
Next, we questioned whether our results extended in vivo, and whether T cells differentiate in an 261 
altered manner in cathelicidin knockout (Camptm1Rig, KO) mice. Firstly we assessed whether KO 262 
mice had altered Th17 cell numbers in the steady state. Analysis of ex vivo T cell cytokine 263 
production in multiple organs revealed no differences between KO and wildtype 264 
12 
 
C57BL/6JOlaHsd (WT) mice (Fig.7A,B) – indicating that cathelicidin is not required for 265 
development of Th17 cells in the steady state. 266 
We hypothesised that while cathelicidin has no impact on T cell development, it may affect Th17 267 
differentiation during inflammation, when it is released by neutrophils and other cells. To 268 
investigate the impact of cathelicidin in the context of inflammation, we used a vaccination 269 
model.  WT and KO mice were inoculated with heat killed Salmonella typhimurium (HKST) into 270 
the top of each hind paw. Seven days later draining popliteal lymph nodes were removed and 271 
IL-17A quantified by flow cytometry. KO lymph node CD4+ T cells were unable to produce IL-272 
17A to the same level as WT T cells (Fig.7C), confirming that cathelicidin promotes Th17 273 
differentiation in vivo as well as in vitro.  274 
This experiment did not tell us if the T cells themselves were inherently different in KO mice or 275 
unable to produce IL-17. To test this, we firstly stimulated KO splenic T cells in vitro. In the 276 
presence of Th17-driving cytokines, CD4+ T cells from KO mice could produce IL-17 to a level 277 
equivalent to wildtype cells (Fig.7D). Secondly, we performed an adoptive transfer of OT-II CD4+ 278 
T cells into WT and KO mice and immunised the mice with ovalbumin in complete Freund’s 279 
adjuvant. Analysis of donor T cells in draining inguinal lymph nodes and spleens 7 days later 280 
showed significantly lower IL-17A production by donor T cells introduced into KO mice (Fig.7E). 281 
In addition, the percentage (Fig.7F) and number (Fig.7G) of OT-II cells recovered from KO mice 282 
was significantly lower than WT mice, supporting our earlier in vitro findings that cathelicidin 283 
enhances survival of these cells. These two experiments combined led us to conclude that a) 284 
cathelicidin is not absolutely required for Th17 differentiation or for baseline production of IL-17 285 
but b) in the context of inflammation, cathelicidin potentiates Th17 differentiation and IL-17 286 
production. They also demonstrated that our in vitro observation that cathelicidin is a Th17 287 




Cathelicidin is released in the lymph nodes by neutrophils 290 
Repeating our in vitro culture experiments with Th17-driving medium, we found that cathelicidin 291 
needed to be present in the first 24 hours of culture in order to induce Th17 differentiation 292 
(Fig.8A), with its addition to activated cells leading to no differences in IL-17 production. This 293 
suggests that, in vivo, it would only promote Th17 differentiation if present in lymph nodes 294 
during the antigen presentation process, and would not have an enhancing effect in the tissue if 295 
interacting with T cells which are already activated and differentiated.  296 
We did not know whether or when cathelicidin was produced in the lymph nodes. To determine 297 
this, we examined lymph nodes over a time course of HKST injection. Cathelicidin was not 298 
present in the steady state lymph node but appeared on day one following inoculation and was 299 
strongly present at day 7 (Fig.8B). Interestingly, we noted the presence of extracellular 300 
cathelicidin (arrow heads, Fig.8B) which had been released from cells.  301 
Co-staining lymph node sections revealed that the vast majority of cathelicidin-expressing cells 302 
were neutrophils, with 85% of cathelicidin signal on day 7 being associated with co-staining for 303 
the neutrophil marker Ly6G (total cathelicidin+ cells counted over three lymph nodes = 366, of 304 
which 55 were Ly6G- and 311 Ly6G+) (Fig. 8C). We therefore hypothesised that neutrophils 305 
were releasing cathelicidin in the lymph nodes and enhancing Th17 differentiation.  306 
Firstly, we confirmed that KO mice did not have an intrinsic defect in neutrophil migration. 307 
Following HKST inoculation, neutrophil numbers in the draining lymph node were equivalent 308 
between WT and KO mice (Fig,8D). Next, we examined IL-1β in this system. We did not note a 309 
significant change in lymph node IL-1β following HKST inoculation in WT compared to KO mice 310 
(Fig.8E). 311 
We examined whether neutrophil release of cathelicidin could induce Th17 differentiation in 312 
vitro. Neutrophil-induced production of IL-17 has previously been demonstrated [86]. Here, we 313 
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used mouse bone-marrow isolated neutrophils from WT or KO mice, which had been activated 314 
by 30 minutes’ incubation with fMLF and cytochalasin B, to induce de-granulation. The 315 
neutrophils were included in culture wells with WT CD4+ T cells, at a 1:1 T cell: neutrophil ratio 316 
and in Th17-driving conditions. WT neutrophils induced IL-17A production by CD4+ T cells 317 
(Fig.8F) but KO neutrophils did not, although the positive control cathelicidin demonstrated that 318 
the experiment had worked as normal (Fig.8G). This data demonstrates that the increase in IL-319 
17A production induced by de-granulating neutrophils is owing to their release of cathelicidin. In 320 
addition, AhR expression was significantly lower in T cells co-cultured with KO neutrophils 321 
compared to WT neutrophils (Fig.8H) and blocking cathelicidin from WT neutrophils with an 322 
antibody suppressed IL-17A enhancement from sorted CD4+ T cells (Fig.8I). Finally, we 323 
examined responses to an infection model in addition to vaccination. As cathelicidin is directly 324 
antimicrobial, it is difficult to decipher its immunomodulatory roles separately to its microbial 325 
killing. However, we have previously demonstrated that cathelicidin dramatically enhanced 326 
survival in a murine influenza virus infection model, despite only small changes in viral load, 327 
suggesting a key immunomodulatory component to protection [87]. We therefore infected WT 328 
and cathelicidin KO mice with PR8 influenza and removed the draining mediastinal lymph nodes 329 
on day 3 post infection. In agreement with the evidence presented in this paper, IL-17A 330 
production in the KO mice was substantially (but not totally) suppressed, when compared to WT 331 
mice (Fig.8J). 332 
Cathelicidin induces IL-17A production from human CD4+ T cells 333 
Finally, to assess whether our observations held true for human cells, we isolated CD4+ T cells 334 
from peripheral blood of healthy human donors and incubated them with 2.5 µM human 335 
cathelicidin (LL-37) under Th17-driving conditions. Production of IL-17A was greater in 336 
cathelicidin-exposed cells than in controls, measured by flow cytometry on day 8 of culture 337 
(Fig.9A,B) and ELISAs on days 3 and 8 (Fig.9C). In addition, IL-17F was also produced at 338 
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higher levels in response to cathelicidin (Fig.9D). Interestingly, in contrast, IL-22 production was 339 
lower after cathelicidin exposure (Fig.9E). 340 
 341 
DISCUSSION 342 
We demonstrate that the mouse and human antimicrobial host defence peptide cathelicidin (LL-343 
37/ mCRAMP) induces differentiation of Th17 cells in vitro and in vivo. Specifically, CD4+ T cells 344 
exposed to cathelicidin a) up-regulated AHR, RORγt, IL-17A and IL-17F b) down-regulated IL-2, 345 
IFN-γ and Tbet and c) survived in greater numbers than their untreated controls. This work 346 
extends previous studies showing that neutrophils and Th17 cells amplify each others’ 347 
responses (reviewed in [18]), providing an explanation for how neutrophils specifically promote 348 
one subset of T cells above others. 349 
Cathelicidin exposure led to a 6-fold increase in production of IL-17A in sorted CD4+ T cells 350 
(Fig.1D), and a 2.5-fold increase in production by CD4+ T cells in whole splenic cultures 351 
(Fig.1E). This compares to a 2.5-fold increase in IL-17A production by the aryl hydrocarbon 352 
receptor FICZ [75] and a 3-4-fold increase in IL-17A mRNA by the same reagent [73]. These 353 
results therefore identify cathelicidin as of equal potency to one of the most important Th17 354 
inducers known.  355 
We show that cathelicidin specifically increases frequency of and cytokine production by those 356 
cells which produce IL-17F as well as IL-17A, with seemingly separate pathways promoted in 357 
each case. Antagonism of the AHR pathway led only to a suppression in cathelicidin’s induction 358 
of cells producing IL-17A and not in the induction of IL-17F sole producers (Fig.3G,H). 359 
Previously, triggering of AHR with FICZ led to an increase in IL-17A sole producers and IL-360 
17A+F+ dual producers, but led to a decrease in IL-17F single positive cells [73]. This, along with 361 
our data, implies that there may be two pathways promoted by cathelicidin: one of which is 362 
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AHR-dependent, and which enhances IL17A+F+ production; and one which is AHR-363 
independent and which enhances IL-17F production alone. This may also explain the interesting 364 
lack of difference in IL-22 production by cathelicidin-treated mouse cells, and its suppression in 365 
human cells, as this has also been shown to be driven by AHR ligation [73]. Single-cell 366 
transcriptome and signalling pathway analysis of whole splenic cultures treated with cathelicidin 367 
will be required to test this hypothesis, and to extend our understanding of how cathelicidin is 368 
enhancing TGF-β1 and AHR signalling. 369 
The up-regulation of RORγt and down-regulation of Tbet induced by cathelicidin was dependent 370 
on the presence of TGF-β1 in the differentiation cocktail, and cathelicidin enhanced 371 
phosphorylation of SMAD2/3, which mediate TGF-β1 signals [63]. TGF-β1 has been used to 372 
differentiate mouse and human Th17 cells in many studies [88] [89], and cathelicidin could not 373 
induce Th17 cells in its absence, but rather enhanced its effects. Interestingly, cathelicidin did 374 
not enhance IL-1 β-induced Th17 differentiation, indicating that the cathelicidin-mediated 375 
increase in AHR and IL-17A was a result of enhanced TGF- β1 signalling rather than a more 376 
general Th17-boosting phenomenon. 377 
The necessity for TGF-β1 in cathelicidin’s induction of Th17 cells extends previous observations 378 
of interplay between these two mediators in other cell types [90-92]. Neutrophils can produce 379 
TGF-β in lymph nodes and in tissues. Interestingly, lymph node-neutrophil inhibition of B cell 380 
activation following inoculation is also TGF-β dependent [23]. Deposition of granule proteins in 381 
the lymph node by de-granulating neutrophils has been demonstrated previously [21] and the 382 
presence of extracellular cathelicidin in our lymph nodes following HKST inoculum supports our 383 
hypothesis that deposition of this peptide is also occurring during inflammation, alongside 384 
production of TGF-β from multiple cell types. This allows the enhanced differentiation of Th17 385 
cells during inflammation.  386 
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Exposure of CD4+ T cells to cathelicidin under Th17-driving conditions led to an almost 387 
complete suppression of IL-2 production, an enhancement of that noted previously as induced 388 
by AHR signalling [82]. This observation is intriguing. It would predict that T cells exposed to 389 
cathelicidin, in the presence of de-granulating or NETosing neutrophils, will proliferate less, as 390 
the available IL-2 is reduced. Further, neutrophil-induced suppression of T cell proliferation is 391 
well documented [22, 93]. Indeed, we demonstrate that cathelicidin inhibited proliferation of 392 
Th17 cells in culture and therefore suggest that the neutrophils’ release of cathelicidin, and 393 
subsequent suppression of IL-2 production, is one mechanism behind this phenomenon.  394 
The increased survival specifically of Th17 cells following cathelicidin exposure is interesting. 395 
Neutrophil-boosted survival of any T cell subset has never previously been described. 396 
Neutrophils can release BAFF and APRIL in the lymph nodes and thus protect B cells against 397 
apoptosis [94-96], and can also enhance NK cell survival [97], meaning our demonstration of T 398 
cell survival fits within the context of the wider lymphocyte population.  399 
Th17 cells are associated with a number of inflammatory and autoimmune conditions, including 400 
psoriasis, rheumatoid arthritis, and type 1 diabetes (reviewed in [98]). Our work supports 401 
previous data showing that cathelicidin is recognised by some CD4+ T cells as an auto-antigen 402 
during psoriasis, and those T cells which recognise cathelicidin produce more IL-17 [58]. The 403 
phenotype of the T cells resulting from cathelicidin exposure–proliferating less, but surviving 404 
longer, and producing more pro-inflammatory cytokines – suggests that they would be 405 
deleterious long-term, and therefore that neutrophils present during these conditions could be 406 
responsible for increased disease onset and severity. In this regard, however, the specific 407 
increase in IL-17F producing cells by cathelicidin is interesting, as this cytokine has been 408 
correlated with non-pathogenicity of cells [99, 100], and the spinal-cord infiltrating Th17 cells in 409 
EAE are mostly solely producing IL-17A [100]. Future work understanding the role of neutrophil-410 
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released cathelicidin in altering the pathogenicity of Th17 cells, and in the specific induction of 411 
IL-17F, will be of great interest. 412 
Whether cathelicidin enters T cells through a specific receptor is unclear. We demonstrate that 413 
the D-enantiomer of human cathelicidin induces Th17 differentiation, strongly suggesting the 414 
peptide can enter T cells in a receptor-independent fashion, as it can do to other immune cells. 415 
However, our data showed a suppression of Th17 differentiation in the presence of oATP, an 416 
inhibitor of the receptor P2X7. This was not statistically significant, and interpretation is 417 
complicated by a) significantly enhanced cell death in T cells exposed to oATP, b) an increase 418 
in baseline IL-17 production in T cells exposed to oATP but not to cathelicidin, and c) the fact 419 
that oATP is not only a P2X7 inhibitor but also attenutates inflammation by P2X7-independent 420 
mechanisms [101]. We infer from these data that there may be an indirect mechanism involving 421 
P2X7 in cathelicidin-mediated Th17 differentiation, but unravelling this mechanism will require 422 
knockout mice or more precise inhibitors than oATP. 423 
Overall, our study identifies the antimicrobial peptide cathelicidin as a key Th17 differentiation 424 
factor and defines one mechanism by which neutrophils can alter developing T cell responses in 425 




EXPERIMENTAL DESIGN 428 
All experiments were performed three times on individual mice or donor cell cultures and then 429 
power calculations performed to determine necessary group sizes. Both male and female mice 430 
and human donors were used in experiments and no differences were noted in responses 431 
between the sexes. Numbers of individuals and of experiments are listed in each figure legend. 432 
Mice were housed together for in vivo experiments to avoid cage-specific effects.  433 
MICE 434 
Wild type C57Bl/6JOlaHsd and mCRAMP knockout (Camptm1Rig, KO) mice were bred and 435 
housed in individually ventilated cages, under specific pathogen-free conditions. Male and 436 
female mice between 6-12 weeks of age were used. KO mice were backcrossed onto wildtypes 437 
for 10 generations before use. Mice were kept in environmental conditions in line with the ASPA 438 
Code of Practice for the UK – temperatures between 19 and 24oC, humidity between 45 and 439 
65%, and 12 hours of light then 12 hours of dark. 440 
All animal experiments were performed by fully trained personnel in accordance with Home 441 
Office UK project licences PAF438439 and 70/8884, under the Animal (Scientific Procedures) 442 
Act 1986. All relevant ethical regulations for animal research were fully complied with. The 443 
experimental program of work was described in project licence PAF438439 and was approved 444 
as such. Each experimental protocol was overseen by the in-house University of Edinburgh 445 
veterinary team. 446 
HEALTHY HUMAN DONORS 447 
Peripheral venous blood was collected from healthy adult volunteers under ethical agreement 448 
code AMREC 15-HV-013. All ethical regulations from the University of Edinburgh were adhered 449 
20 
 
to and informed written consent was obtained from every donor. Experimental programs were 450 
overseen by the University of Edinburgh Centre for Inflammation Research Blood Resource 451 
Management Committee. Up to 160ml of blood was collected at one time into sodium citrate 452 
and was then processed immediately. Ficoll Paque Plus (GE Healthcare #GE17-1440-02) was 453 
used to isolate mononuclear cells by mixing with freshly isolated blood (1:1 diluted in PBS) and 454 
spinning in LeucoSep tubes (Grenier #227289) for 15 minutes at 1000g, with brake at 0. CD4+ T 455 
cells were then isolated from the cell layer using the EasySepTM human CD4+ T cell isolation kit 456 
(StemCell Technologies #17952), according to manufacturers’ instructions.  457 
HUMAN TH17 CULTURES 458 
Human CD4+ T cells were plated at 1x105 cells/well in a round-bottom 96-well plate in complete 459 
medium (RPMI, 10% fetal calf serum, 10 units/mL penicillin, 10 μg/mL streptomycin and 2 mM 460 
L-glutamine, all supplied by Gibco, ThermoFisher UK). Cytokines added were: 10ng/ml TGF-β1 461 
(Biolegend #580702), 100ng/ml IL-6 (Biolegend #570802), 30ng/ml IL-1β (Biolegend #479402), 462 
30ng/ml IL-23 (Biolegend #574102) and 2.5µl/ml anti-CD3/23/2 ImmunoCult T cell activator 463 
(StemCell Technologies #10970). Medium was changed on day 3 and samples were assessed 464 
by flow cytometry and ELISA on day 8. 465 
PEPTIDES 466 
Synthetic mCRAMP (GLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPEQ) and LL-37 467 
(LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES) were custom synthesized by Almac 468 
(Penicuik, Scotland) using Fmoc solid phase synthesis and reverse phase HPLC purification. 469 
Peptide identity was confirmed by electrospray mass spectrometry. Purity (>95% area) was 470 
determined by RP-HPLC and net peptide content determined by amino acid analysis. D-471 
enantiomer LL-37 was a kind gift from Professor Peter Barlow, Edinburgh Napier University. 472 
Lyophilized peptides were reconstituted in endotoxin free water at 5 mg/ml. Reconstituted 473 
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peptides were tested for endotoxin contamination using a Limulus Amebocyte Lysate 474 
Chromogenic Endotoxin Quantitation Kit (Thermo Scientific, UK #88282). 475 
MURINE TISSUE AND SINGLE CELL PREPARATIONS  476 
Mice were culled by rising concentrations of CO2, followed by cervical dislocation. Single cell 477 
preparations of spleens, lymph nodes and Peyer’s patches were achieved by mashing the 478 
tissues through a 100 μM strainer and washing with PBS.  One lung lobe was minced and 479 
enzymatically digested with 1mg/ml collagenase VIII (Sigma Aldrich, #C2139) for 20 mins at 480 
37°C, with shaking before the cell suspension was passed through a 100 μM filter. To isolate 481 
liver leukocytes, one lobe was passed through a 100 μM strainer and leukocytes isolated by 482 
Percoll separation  [102]. To do this, cell pellets from straining were re-suspended in 32% 483 
Percoll, 3% 10xPBS, 65% Hanks balanced salt solution. The cells were spun at 600g for 10 484 
minutes. From this, floating hepatocytes were removed and leukocytes collected from the pellet. 485 
In all cases red blood cells were lysed using RBC Lysis Buffer, as per the manufacturer’s 486 
instructions (BD Biosciences, #555899).  487 
ISOLATION OF BONE MARROW-DERIVED NEUTROPHILS 488 
Femurs were removed and marrow flushed out with complete medium (RPMI, 10% fetal calf 489 
serum, 10 units/mL penicillin, 10 μg/mL streptomycin and 2 mM L-glutamine, all Gibco, 490 
ThermoFisher UK). Single cell suspensions were prepared by passing the cells through a 19G 491 
needle. Neutrophils were isolated using the EasySepTM Mouse Neutrophil Enrichment Kit 492 
(StemCell Technologies, #19762), as per the manufacturer’s guidelines. Neutrophils were 493 
activated by 30 minutes’ incubation with 100 nM fMLF (N-formylmethionine-leucyl-494 
phenylalanine, Sigma Aldrich #F3506) and 10 µM cytochalasin B (Sigma Aldrich #C2743) 495 
before being well washed twice. 496 
IN VITRO T HELPER CELL SUBSET DIFFERENTIATION 497 
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Whole splenocytes were prepared as above. CD4+ T cells were isolated from whole splenocytes 498 
by FACS sorting on a BD Biosciences Aria sorter using a 70µM nozzle or using the EasySep 499 
mouse CD4+ T cell isolation kit (StemCell Technologies, Cat #19852). Purity achieved with both 500 
methods was always over 95%.  501 
200,000 cells were plated per well of round-bottom 96-well plates in complete medium (RPMI, 502 
10% fetal calf serum, 10 units/mL penicillin, 10 μg/mL streptomycin and 2 mM L-glutamine, all 503 
supplied by Gibco, ThermoFisher UK), with the correct combination of cytokines and 504 
neutralizing antibodies as follows. Th1 cells were differentiated for 4 days in the presence of 505 
plate-bound αCD3 (5 µg/ml; Biolegend, #100339), rIL-12 (25 ng/ml; Biolegend, #575402), rIL-18 506 
(25 ng/ml; Gibco, #PMC0184) and rIL-2 (10 U/ml; Biolegend, #575402), with or without 2.5 μM 507 
mCRAMP. Th2 cells were cultured for 4 days with plate-bound αCD3 (5 µg/ml; Biolegend, 508 
#100339), rIL-4 (4 ng/ml; Peprotech, #214-14), rIL-2 (40 U/ml; Biolegend, #575402), αIL-12 (5 509 
µg/ml; Biolegend, #505307) and αIFNγ (5 ug/ml; Biolegend, #505812), with or without 2.5 μM 510 
mCRAMP. Th17 cells were differentiated in the presence of plate-bound αCD3 (5 µg/ml; 511 
Biolegend, #100339), rIL-6 (20 ng/ml; Biolegend, #575706), rIL-23 (20 ng/ml; Biolegend, 512 
#589006) and rTGFβ (3 ng/ml; Biolegend, #580706), with or without 2.5 μM mCRAMP for 1 to 3 513 
days. αCD28 (1 µg/ml; Biolegend, #102115) was added to cultures of pure CD4+ T cells. In 514 
some experiments neutrophils, isolated as above, were incubated in CD4+ T cell cultures at a 515 
1:1 neutrophil: T cell ratio. In other experiments recombinant IL-2 (Biolegend, #575402) or 516 
recombinant IL-1β (RnD Systems, #401-ML) were included in cultures. 517 
FLOW CYTOMETRY  518 
Cells were stained for surface markers for 30 mins at 4°C, protected from light. Intracellular 519 
cytokines were assessed by incubating cells for 4 hours at 37°C with Cell Stimulation Cocktail 520 
containing protein transport inhibitors (eBioscience, #00-4970-03). Cells were fixed, 521 
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permeabilised and stained for cytokines using BD Cytofix/Cytoperm (BD Biosciences, #554722), 522 
as per the manufacturer’s guidelines. Cells were fixed, permeabilised and stained for 523 
transcription factors using the True-Nuclear Transcription Factor Buffer Set, as per the 524 
manufacturer’s instructions (Biolegend, #424401). Cell viability was assessed by flow cytometry 525 
using the Annexin-V-FLUOS Staining Kit, as per the manufacturer’s guidelines (Roche, #11 858 526 
777 001) or fixable live/dead yellow (ThermoFisher #L34959). To assess proliferation, cells 527 
were stained with carboxyfluorescein succinimidyl ester at 1:2000 dilution for 10 minutes 528 
(Invitrogen, #C34554) before culture. Proliferation analysis by dye dilution was performed by 529 
flow cytometry. Samples were collected using an LSRFortessa cytometer(BD Biosciences) and 530 
Diva software version 9, and analysed using FlowJo software version 10 (BD Biosciences).  531 
Flow cytometric analysis of phosphorylated antigens was performed by first staining surface 532 
markers for 30 mins at 4oC, before adding 1ml of phosflow lyse/fix buffer (BD Biosciences, Cat 533 
#558049) for 60 minutes at room temperature. Cells were then centrifuged and resuspended in 534 
1ml ice-cold methanol for 30 minutes on ice before being washed with PBS. Antibodies in PBS 535 
were used to stain intracellular phosphorylated antigens for 45 minutes before being washed 536 
and data collected immediately.  537 
ANTIBODIES (MOUSE) 538 
CD4 (clone GK1.5, Biolegend, #100453, dilution 1:200); CD8 (53-6.7, BD Biosciences, 539 
#563786, 1:200); IFNγ (XMG1.2, Biolegend, 505825, 1:100); IL-17A (TC11-18H10.1, Biolegend, 540 
#506938, 1:100); IL-22 (POLY5164, Biolegend, #516411, 1:100); RORγT (B2D, eBiosciences, 541 
#12-6981-80, 1:100); TBET (4B10, Biolegend, #644805, 1:100); AHR (4MEJJ, eBiosciences, 542 
#25-5925-80, 1:100); pSTAT3 (LUVNKLA, eBioscience, #11-903-42, 1:100); pSMAD2/3 (o72-543 
670, BD Biosciences, #562586, 1:100) 544 
ANTIBODIES (HUMAN) 545 
24 
 
CD4 (clone OKT4, eBioscience #25-0048-42, 1:200), IL-17A (eBio64DEC17, eBioscience #12-546 
7179-42, 1:100), IL-17F (Poly5166, Biolegend #516604, 1:150). 547 
NANOSTRING  548 
Mouse Th17 cultures were set up as previously described. DAPI-γδ-CD4+ T cells were sorted 549 
using a BD FACSAriaTM II (BD Biosciences) on day 1. RNA was extracted immediately using the 550 
Qiagen RNeasy Mini Kit (Qiagen, #74104), as per the manufacturer’s guidelines. Multiplex gene 551 
expression analysis (Mouse Immunology Panel) was performed by HTPU Microarray Services, 552 
University of Edinburgh. Data analysis was performed using nSolver 4.0 and nCounter 553 
Advanced Analysis software. Genes with a log2 fold change of 1 or more and a p value of 0.05 554 
or less, following correction for multiple comparisons, were deemed of interest and statistically 555 
significant.  556 
ELISAs 557 
Concentrations of mouse IL-17A (Biolegend, #432504), IFNγ (Biolegend, #430804), IL-2 558 
(Biolegend, #431004), IL-17F (Biolegend, #436107) and IL-22 (Biolegend, #436304), and of 559 
human IL-17A (Invitrogen #BMS2017) and IL-22 (ThermoFisher, #BMS2047) were determined 560 
in cell culture supernatants by ELISA, as per the manufacturer’s guidelines. 561 
IMMUNOHISTOCHEMISTRY 562 
Lymph nodes were fixed in 10% neutral buffered formalin and embedded in paraffin. 10 µm 563 
sections were deparaffinized and antigens retrieved by microwaving in tri-sodium citrate buffer, 564 
pH6 for ten minutes, or by ten minutes’ incubation with 5mg/ml proteinase K (ThermoFisher UK 565 
#AM2548). Slides were blocked (Avidin/Biotin Blocking Kit, Vector Laboratories, #SP-2001) and 566 
incubated overnight with rabbit anti-mCRAMP (1/250; Innovagen, #PA-CRPL-100). Slides were 567 
then incubated with an anti-rabbit HRP-conjugated secondary antibody (1/500; Dako, #P0217) 568 
or AF488-conjugated antibody (1:500, ThermoFisher UK #A11034). Some sections were 569 
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developed with diaminobenzidine (ImmPACT DAB Peroxidase (HRP) Substrate, Vector 570 
Laboratories, #SK-4105) and others were also incubated with an AF647 anti-neutrophil antibody 571 
(1:50, Biolegend UK #127609). Slides were scanned on a ZEISS Axio Scan.Z1 slide scanner.  572 
HEAT-KILLED SALMONELLA MODEL  573 
Heat-killed salmonella was a kind gift from Professor Andrew Macdonald, MCCIR, University of 574 
Manchester. 12.5 μg heat-killed Salmonella typhimurium in 50 µl PBS was injected 575 
subcutaneously in the top of each hind paw. Mice were monitored and the draining popliteal 576 
lymph nodes removed after 1, 3 or 7 days. Nodes were either fixed in 10% neutral buffered 577 
formalin and embedded in paraffin for sectioning, or single cell suspensions were prepared as 578 
described previously for flow cytometric analysis. 579 
INFLUENZA INFECTION MODEL 580 
Murine influenza strain PR8 was instilled intra-nasally into mice – 12pfu in 40ul inoculations. 581 
Mice were monitored daily and the draining mediastinal lymph nodes removed 72 hours later. 582 
Flow cytometry on node single cell suspension was performed as previously described. 583 
STATISTICS 584 
All data shown are expressed as individual data points with line at median. Analysis was 585 
performed with GraphPad Prism software. Multiple groups were compared by one- or two-way 586 
analysis of variance tests with either Bonferroni or Dunnett post-tests. Two groups were 587 
compared with two-way paired Student’s t-tests. A minimum of three mice was used for in 588 
vitro experiments, in individually performed experiments. Details of sample sizes are included in 589 
all figure legends. 590 
 591 
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 836 
FIGURE LEGENDS 837 
Figure 1: The antimicrobial peptide cathelicidin induces IL-17A production by CD4+ T 838 
cells. Splenocytes isolated from C57BL/6J mice were cultured in Th17-driving conditions for 48 839 
hours in the presence or absence of 2.5μM murine cathelicidin. (A,B) Expression of cytokines 840 
was determined by intracellular flow cytometry. (C) Splenocytes were cultured with αCD3αCD28 841 
stimulation alone with cathelicidin. (D) Production of IL-17A following increasing doses of 842 
cathelicidin (for 48 hours) and (E) prodution over increasing days in culture was assessed. (F) 843 
Geometric mean of IL-17A expression was also assessed at 48 hours. (G) After 72 hours of  844 
culture supernatant was collected and IL-17A protein quanitified by ELISA. (H) Representative 845 
flow cytometry plots showing RORγt expression; (I) RORγt expression was quantified over time 846 
in culture. (J) At 48 hours in culture all IL-17+ cells were RORγt+. (K) Sorted CD4+ T cells were 847 
cultured alone in Th17-driving confitions for 48 or 72 hours. (L-N) Following 24 hours’ culture of 848 
sorted CD4+ T cells STAT3 phosphorylation was assessed by flow cytometry. Data shown are 849 
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individual mice used in separate experiments with line at median. Statistical signficance was 850 
determined using a one-way ANOVA with Sidak‘s post-test (E, I), a two-tailed paired t test with 851 
no corrections (B, G, F, G, K, M, N) or a one-way ANOVA with a Dunnett’s multiple comparison 852 
post-test (D). N values: B - 17, C - 6, D - 3, E - 6, F - 24, G - 7, I - 6, K - 4, M - 3, N - 3. Black 853 
symbols represent untreated samples and open symbols represent samples exposed to 854 
cathelicidin. 855 
Figure 2: Cathelidin-mediated induction of IL-17A is dependent on TGF-β signalling. 856 
Splenocytes isolated from C57BL/6J mice were cultured in Th17-driving conditions for 48 hours 857 
in the presence or absence of 2.5μM cathelicidin. (A) Expression of RORγt following incubation 858 
with each component of the Th17 medium was assessed. (B, C) Expression of cell surface 859 
cytokine receptors was quantified by flow cytometry. (D, E) Following 24 hours in culture of 860 
isolated CD4+ T cells, phosphorylation of SMAD2/3 was determined. (F) IL-1β was included in 861 
cell cultures and IL-17A production assessed. (G) Different cathelicidin peptides were included 862 
in the cultures and (H, I) inhibitors of cell surface receptors for cathelicidin. Data shown are 863 
individual mice treated separately with line at median. Statistical significance was deetermined 864 
using a two-way ANOVA with Sidak’s post-test (A, I), a paired two-tailed t test with no 865 
corrections (E, H, F), or a one-way ANOVA with a Tukey’s multiple comparison post-test (G). N 866 
values: A - 4, C - 3 for IL-23R and IL-6r, 4 for TGF-bR, E - 3, F - 3, G - 8 for UT and CRAMP, 3 867 
for LL-37 and D-LL-37, .H - 3, I - 6 for 0nM, 3 for 10 and 50nM. Black symbols rrepesent 868 
untreated samples and open symbols represent samples treated with cathelicidin. 869 
Figure 3: Cathelicidin induces IL-17F-producing but not IL-22-producing T cells. 870 
Splenocytes isolated from C57BL/6J mice were cultured in Th17 conditions for 48 hours in the 871 
presence or absence of 2.5μM cathelicidin. (A-D) Expression of IL-17A and F was determined 872 
by intracellular flow cytometry. (E) IL-17F and (F) IL-22 production was quantified by ELISA of 873 
cell culture supernatant after 48 hours in culture. Data shown are individual mice in separate 874 
experiments. B-F are analysed by paired two-tailed t tests. SP = single positive. N values: B - 9, 875 
C - 9, D - 9, E - 5, F - 4. Black symbols represent untreated samples and open symbols are 876 
samples treated with cathelicidin. 877 
Figure 4: Cathelicidin induces Th17 cells via AHR up-regulation. CD4+ T cells isolated from 878 
C57BL/6J mice were cultured in Th17-driving conditions for 24 hours in the presence or 879 
absence of 2.5μM cathelicidin. (A-C) gene expression differences were assessed by a 880 
Nanostring mouse immunology chip. (D) Representative flow cytometry plots showing aryl 881 
hydrocarbon receptor staining which was assessed over time in culture (E) and over increasing 882 
concentrations of cathelicidin (F). (G,H) IL-17A and F production was assessed by flow 883 
cytometry following blockade of AHR with the antagonist CH223191 (ant.). (I) Th17 cultures 884 
were repeated using IMDM as well as RPMI medium. Data shown are individual mice with line 885 
at medium. Statistical significance was assessed using (B,C) a paired two-tailed t test with 886 
Bonferroni post-test, (E) repeated measures ANOVA with Sidak’s post-test, (F) Kruskal-Wallis 887 
test, (G,H) two-way ANOVA with Tukey’s post-test and (I) two-tailed t test with no correction. N 888 
values: B- 3, C - 3, E - 3, F - 3, G - 5, H - 5, I - 3. The error bars in I show standard error of the 889 
mean. Black symbols represent untreated samples and open symbols are samples treated with 890 
cathelicidin. Red symbols show samples treated with AHR antagonist. 891 
Figure 5: Cathelicidin suppresses TH1 differentiation in the presence of TGF-β1. 892 
Splenocytes from C57BL/6J mice were cultured in Th17-driving conditions for 48 hours in the 893 
presence or absence of 2.5μM cathelicidin. (A) production of IL-2 was quantified by ELISA and 894 
(B-D) expression of Tbet and IFN-γ were assessed by flow cytometry. (E) Tbet and RORγt co-895 
expression was quantified by flow cytometry and (F-H) the cytokine production by each subset 896 
assessed. (I) Tbet expression was determined following incubation with individual cytokines. (J) 897 
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IFN-γ production was quantified by ELISA after 48 hours incubation under Th1-driving or Th2-898 
driving  conditions. Data shown are individual mice used in separate experiments. A, B, D, E, F, 899 
G , H and I were analysed by paired two tailed t tests with no correction, N values: A - 4, B - 6, 900 
D - 12, E - 9, F - 9, G - 9, H - 9, I - 4, J - 3. The error bars in J show standard error of the mean.  901 
Black symbols represent untreated samples and open symbols are samples treated with 902 
cathelicidin. 903 
Figure 6: Cathelicidin protects Th17 cells but not Th1 cells from death. CD4+ T cells 904 
isolated from C57BL/6J mice were cultured in Th17-driving conditions for 24 hours in the 905 
presence or absence of 2.5μM cathelicidin. (A) Gene expression differences were assessed by 906 
Nanostring mouse immunology chip. Cell death was assessed in culture by (B,C) annexin V / 907 
propidium iodide staining and (D-F) binding of a fixable live/dead marker. (G) Annexin/PI 908 
staining was repeated at 48 hours of culture following inclusion of IL-2 in culture medium. (H-J) 909 
T cells were labelled with CFSE and proliferation assessed following 24, 48 or 72 hours culture - 910 
(I) and (J) show 72 hours culture analysis. Data shown are individual mice used in separate 911 
experiments with line at median. A,E, F and I were analysed with paired two-tailed t tests - A 912 
and I with Bonferroni post correction, C and G with a two-way ANOVA with Sidak’s post-test. N 913 
values: A - 3, C - 6, E - 20, F - 19, G - 5, I - 3, J - 3. Black symbols represent untreated samples 914 
and open symbols are samples treated with cathelicidin. 915 
Figure 7: Mice lacking cathelicidin cannot increase IL-17A production in response to 916 
inflammation. Wildtype (WT) C57BL/6J and fully backcrossed cathelicidin knockout (Camp-/-, 917 
KO) mice were culled and (A, B) organs removed and IL-17A production assessed ex vivo by 918 
flow cytometry. (C) Mice were inoculated with 12.5μg/ml heat-killed Salmonella typhimurium and 919 
draining lymph nodes removed seven days later - IL-17A was measured by flow cytometry. (D) 920 
Splenic T cells from WT or KO mice were stimulated in Th17-driving conditions for 48 hours and 921 
IL-17A quantified by flow cytometry. (E-G) WT and KO mice were injected intravenously with 5 922 
million OT-II T cells and 24 hours given ovalbumin in complete Freund’s adjuvant sub-923 
cutaneously. On day 7 spleens and lymph nodes were removed and donor cell survival and IL-924 
17A production assessed by flow cytometry. Data shown are individual mice with line at median. 925 
C-G were analysed with two-tailed t tests with no correction. PP - Peyer’s Patches; mLN = 926 
mesenteric lymph node. N values: B - 4, C - 3, D - 4, E - 4, F - 4, G - 4. Black symbols represent 927 
wildtype mice and open symbols represent mice lacking cathelicidin. 928 
Figure 8: Cathelicidin is released in the lymph node by neutrophils. (A) IL-17A production 929 
was assessed by flow cytometry following cathelicidin being added to mouse Th17-driving 930 
cultures on day 0 or day 1. (B,C) Wildtype C57BL/6J mice were inoculated with 12.5 μg heat-931 
killed Salmonella typhimurium (HKST) and draining lymph nodes removed 7 days later. Lymph 932 
nodes on day 0 and 7 were assessed for presence of cathelicidin (B, arrow heads indicate 933 
cathelicidin not associated with cells) and the association of cathelicidin with the neutrophil 934 
marker Ly6G (C). (D) HKST inoculation of WT and cathelicidin knockout (KO) mice was 935 
performed and 24 hours later infiltration of neutrophils into the draining popliteal lymph nodes 936 
quantified by flow cytometry. (E) IL-1β release was also quantified at 24 hours post inoculation. 937 
Neutrophils were isolated from the bone marrow of (F) WT and (G) KO mice, primed, and added 938 
to Th17-driving cultures of splenic T cells for 48 hours before IL-17A production was assessed 939 
by flow cytometry and (H) AHR expression was assessed. (I) primed neutrophils from WT mice 940 
in the presence or absence of a cathelicidin-blocking antibody were included in Th17 cultures 941 
and IL-17A assessed. (J) WT and KO mice were infected intra-nasally with 12pfu PR8 influenza 942 
and draining mediastinal lymph nodes removed 72 hours later. IL-17A production was quantified 943 
by flow cytometry. Data shown are individual mice with line at median, B and C are 944 
representative of 3 experiments. Statistical tests used: A,  I - one way ANOVA with Dunnett’s 945 
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post-test; E, F, G, H and J - paired two-tailed t test with no correction. N values: A - 3, D - 3, E - 946 
3, F - 8, G - 3, H - 5 for cath., 4 for neutrophils, I - 3, J - 3. The error bars in H show standard 947 
error of the mean. Black symbols – untreated samples, open symbols - cathelicidin treated. Red 948 
closed symbols - exposed to wildtype neutrophils, red open symbols - exposed to KO 949 
neutrophils. Red triangles - exposed to neutrophils and anti-cathelicidin. 950 
Figure 9: Human CD4+ T cells enhance IL-17 production following cathelicidin exposure. 951 
CD4+ T cells were isolated from peripheral blood from healthy human donors and cultured for 8 952 
days in Th17-driving conditions, in the presence or absence of 2.5μM human cathelicidin (LL-953 
37). IL-17A production was assessed by (A,B) flow cytometry on day 8 and (C) ELISA on days 3 954 
and 8 of culture. (D) IL-17F was assessed by flow cytometry and (E) IL-22 by ELISA. Data 955 
shown are individual donors with line at mean. B- E were analysed by a two-sided Wilcoxon 956 
test, on raw data before conversion to %. N values: B - 11, C - 11, D - 6, E - 3. Black symbols 957 
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